Kiadis names former Ablynx exec as CSO
Dutch biopharma Kiadis Pharma (Euronext: KDS) has announced the appointment of Robert Friesen as chief scientific officer (CSO) effective February 1, 2019.
Dr Friesen will lead the company's science, discovery and pre-clinical development activities and will be instrumental in building the company’s scientific platform and identifying other programs for potential in-license. Dr Friesen will report to Kiadis chief executive Arthur Lahr and will be a member of the company’s management team
Dr Friesen has more than 20 years of experience in the biopharmaceutical industry, leading multiple R&D organizations. He joins Kiadis from Ablynx where he was CSO until its acquisition by Sanofi (Euronext: SAN). At Ablynx, Dr Friesen oversaw a team of more than 300 people who were responsible for more than 40 development-stage product candidates across a wide range of diseases.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze